Título del libro: Inflammatory Breast Cancer
Título del capítulo: Target therapy in inflammatory breast cancer
CESAR ALEJANDRO ARCE SALINAS; JOSE LUIS AGUILAR PONCE; OSCAR GERARDO ARRIETA RODRIGUEZ;
Autores externos:
Idioma:
Inglés
Año de publicación:
2012
Resumen:
Systemic treatment with chemotherapy (CT) and other target therapies is the cornerstone in the treatment of the inflammatory breast cancer (IBC). Completeness a distinctive biological characterize and separate IBC from noninflammatory breast cancer. These are characteristics that are associated with poor prognosis and include a high S-phase fraction, high grade, aneuploidy, loss of hormonal receptors, and overexpression of human epithelial receptor-2 (HER2), p-53-level mutations. IBC overexpresses E-cadherin, a calcium-regulating transmembrane glycoprotein that promotes cell-cell adhesion, and through this, promotes invasion with tumor emboli of the dermal lymphatic system. Dysregulation of p27kip1, a cyclin-dependent kinase (CDK), and high endothelial-cell proliferation, and the expression of lymphangiogenetic factors (VEGF-C, VEGF-D, VEGFR-3, Prox-1), and the lymphatic vascular endothelial receptor 1 and angiogenic factors (Basic fibroblast growth factor [bFGF], Vascular endothelial growth factor [VEGF], Interleukin-6 [IL-6], and IL-8). The advent of new biological treatments has represented an additional benefit because the percentages of pathological response (PR) have improved, and there is even better prognosis. At present, the target therapy is a new therapeutic resource, and progress is being made toward new horizons in the management of inflammatory breast cancer (IBC). © 2013 Springer-Verlag London.
Entidades citadas de la UNAM:
ISBN:
9780857299918
Editorial:
Springer-Verlag London Ltd Nombre de la publicación:
Target therapy in inflammatory breast cancer
Página inicial:
119
Página final:
127
